Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Liabilities and Shareholders Equity (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $259.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 31.5% to $259.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 27.57% decrease, with the full-year FY2025 number at $259.1 million, down 31.5% from a year prior.
  • Liabilities and Shareholders Equity was $259.1 million for Q4 2025 at Phathom Pharmaceuticals, up from $240.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $413.8 million in Q4 2023 to a low of $144.0 million in Q1 2023.
  • A 4-year average of $267.1 million and a median of $254.7 million in 2025 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 151.1% in 2023, then crashed 37.92% in 2025.
  • Phathom Pharmaceuticals' Liabilities and Shareholders Equity stood at $164.8 million in 2022, then surged by 151.1% to $413.8 million in 2023, then decreased by 8.58% to $378.3 million in 2024, then tumbled by 31.5% to $259.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Liabilities and Shareholders Equity are $259.1 million (Q4 2025), $240.3 million (Q3 2025), and $250.2 million (Q2 2025).